Source: Virtual Congress 2021 – ALERT: bronchiectasis and COVID



Rating:

Share or cite this content

Citations should be made in the following way:
C. Fernandez (Bridgewater, United States of America), C. Rubino (Schenectady, United States of America), A. Teper (Bridgewater, United States of America), H. Usansky (Bridgewater, United States of America), J. Chalmers (Dundee, United Kingdom), K. Mange (Bridgewater, United States of America). Exposure-response relationships of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE). 4268

Member's Comments

No comment yet.

Related content which might interest you: Non-cystic fibrosis bronchiectasis: series of 89 patients Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 Non-cystic fibrosis bronchiectasis in children Source: Virtual Congress 2021 – Posters in paediatric bronchology Year: 2021 HRCT features in patients with severe asthma and non-cystic fibrosis bronchiectasis. Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2017; 77: 38-57 Year: 2017 Immuno-allertypes in non-cystic fibrosis  bronchiectasis Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018 Non-cystic fibrosis bronchiectasis Source: Virtual Congress 2020 – Paediatric year in review Year: 2020 Non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2017; 77: 181-198 Year: 2017 Non-cystic fibrosis bronchiectasis Source: International Congress 2019 – Recent clinical advances in inhalation therapy Year: 2019 The pulmonary microbiome in non-cystic fibrosis bronchiectasis. Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017 Exercise capacity in patients with cystic fibrosis vs non-cystic fibrosis bronchiectasis Source: International Congress 2018 – Mechanisms that underlie exercise limitation in various respiratory diseases Year: 2018 Analyses of the relationship between ΔFVC, extent of fibrosis and extent of emphysema in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF clinical Year: 2016 The lung microbiome in chronic suppurative lung disease: cystic fibrosis and non-cystic fibrosis bronchiectasis Source: Eur Respir Monogr 2019; 83: 158-172 Year: 2019 Prevalence of non-cystic fibrosis bronchiectasis in patients with severe asthma: a real-life study Source: Virtual Congress 2020 – Air pollution and comorbidities Year: 2020 Inflammatuary markers in induced sputum and clinical parameters in children with non-cystic fibrosis bronchiectasis Source: Annual Congress 2004 - Chronic respiratory illness in childhood Year: 2004 Physical activity evaluation in non-cystic fibrosis bronchiectasis patients Source: International Congress 2017 – Assessing pulmonary and extra-pulmonary function in chronic disease Year: 2017 Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001 New proteomic biomarkers of cystic fibrosis: a comparison with non-CF bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 240s Year: 2005 Indicators of pulmonary exacerbation in adults with cystic fibrosis (CF) Source: Annual Congress 2011 - Cystic fibrosis: New aspects of diagnosis, inflammation and detecting exacerbation Year: 2011 The relationship of walking speed with clinical parameters in patients with non-cystic fibrosis bronchiectasis Source: Virtual Congress 2020 – Tapas of respiratory physiotherapy Year: 2020